Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
MyMD Pharmaceuticals (Nasdaq: MYMD) recently announced a dosing update for its Phase 2 clinical trial of MYMD-1®, a potential treatment for chronic inflammation caused by sarcopenia and frailty in elderly patients. The trial has successfully dosed 37 out of 40 patients, with no reported safety or toxicity issues among the first 30 patients. The company is progressing into the final cohort of the study, having randomized patients into escalating dose groups. Sarcopenia affects 5-50% of older adults, with no FDA-approved treatments currently available. The aging disorders market is projected to exceed $600 billion by 2025, with TNF-alpha blockers generating approximately $40 billion in annual revenue. MYMD-1® is designed to cross the blood-brain barrier and may offer innovative solutions for aging-related diseases.
MyMD Pharmaceuticals (Nasdaq: MYMD) announced significant preclinical results for its investigational, oral TNF-α inhibitor, MYMD-1®, at the Society of Toxicology Annual Meeting. The study demonstrated that MYMD-1® significantly reduced histopathological changes and arthritis severity metrics compared to placebo, with reductions of 47% in disease severity versus 37% for etanercept. MYMD-1® is noted for its oral administration and ability to cross the blood-brain barrier, positioning it as a promising candidate for rheumatoid arthritis treatment. MyMD is planning early-stage trials and will provide further program guidance.
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) has joined the LOT Network, aimed at protecting against patent assertion entities (PAEs) litigation. This strategic move is designed to safeguard MyMD's intellectual property and resources, allowing the company to focus on its clinical development programs. The LOT Network, comprising over 2,800 companies, provides protection against frivolous lawsuits, which numbered 2,289 in 2022 with an average defense cost of $4 million. MyMD's lead candidate, MYMD-1®, is a promising TNF-alpha inhibitor targeting autoimmune diseases, while its Supera-CBD™ offers potential in managing addiction and pain.